secwatch.observer — SEC 8-K summary
======================================

Issuer:     POINT Biopharma Global Inc. (—)
CIK:        0001811764
Form:       8-K
Filed at:   2023-12-27T23:59:59+00:00
Accession:  0001193125-23-303512
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly completes $12.50/share acquisition of POINT Biopharma; shares to be delisted
--------------------------------------------------------------------------------

- Tender offer expired Dec 22; 72,788,215 shares (68%) validly tendered; Merger effective Dec 27.
- Remaining shares converted into right to receive $12.50 per share in cash, less withholding.
- Board replaced: Gordon Brooks, Phillip Johnson, Michael Thompson become directors; prior directors depart.
- Company requests Nasdaq halt and delisting; plans to file Form 15 to terminate SEC reporting.
- POINT Biopharma 2020 and 2021 equity incentive plans terminated effective at merger close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/0001193125-23-303512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/d594310d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-303512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer